Gemma Sala started their work experience in the Oncology Department of Hospital Vall d'Hebron in 2003 as a Study Coordinator, a position they held until 2007. In 2007, they joined the Vall d'Hebron Institute of Oncology (VHIO) and served as the Head of Phase I Clinical Trials Office for nearly a decade until 2016. From 2016 to 2020, they worked as the Clinical Trials Office Director at VHIO. Currently, Gemma is the Quality & Process Director at VHIO, a position they have held since April 2020.
Gemma Sala completed their Director of Quality Management Systems degree at AENOR in 2021. Prior to that, they obtained a degree in Quality in the Industry and the Pharmaceutical Research from IL3-Universitat de Barcelona in 2018. In 2016, they completed the PADIS-Management/Administration Program in Health Institutions at IESE Business School. Gemma also holds a Master in Clinical Trials Monitoring from Col.legi Oficial de Metges de Barcelona, earned in 2003. Their educational background includes a Biology degree from Universitat de Barcelona, which they completed in 2001.
This person is not in any teams
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.